[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Cryotherapy and Robotic Assisted Non Ischemic Nephron Sparring Surgery


Description

Patients with renal masses eligible to partial nephrectomy often require arterial ischemia to control or prevent blood loss during this surgical procedure. This study aims to determine the safety and efficacy of renal cryoablation at the tumor bed, as a substitute measure or technique vs total or selective arterial renal ischemia.Nephron sparring surgery has emerged as the procedure of choice for most patients with renal tumors that are \>2 cm and harbor a greater than 50% exophitic component. In order to decrease blood loss surgeons may: 1- interrupt blood flow to the kidney, completely or selectively; 2-Use diuretics such as mannitol to dehydrate the kidney; 3-Ice externally the kidney - in open procedures - to decrease metabolism during ischemia. The emergence of robotic surgery triggered a shift in the the surgical approach to partial nephrectomy and is commonly employed. A fundamental drawback of this technique is represented on the lack of cold ischemia. However, warm ischemia i

Trial Eligibility

Inclusion Criteria: * Patients with ages between 45-90-year-old. * Renal tumor ≤ 7 cm in the greatest extension, \>50% exophitic. Exclusion Criteria: * Prior renal surgery * M1 Disease

Study Info

Organization

Urological Research Network, LLC


Primary Outcome

Recurrence - Oncological Control


Outcome Timeframe 10 Years

NCTID NCT05218811

Phases NA

Primary Purpose TREATMENT

Start Date 2020-05-15

Completion Date 2026-05-15

Enrollment Target 150

Interventions

DEVICE Cryoablation Assisted Partial Nephrectomy

Locations Recruiting

Urological Research Network

United States, Florida, Miami Lakes


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Kidney Disease delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.